ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Summary

The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).

Timeline

Start

2021-07

Primary completion

2022-10-30

Completion

2023-04-30

Outcome

Outcome not reported

Stopped: “Study is withdrawn due to the global impact of the COVID-19 pandemic.”

Drugs

Indications